glp-1 by ro See if you qualify Charles Barkley is Ro's GLP-1

86 In patients with T2D and high cardiovascular risk, semaglutide use has resulted in fewer serious cardiac and kidney disorders compared to placebo but is linked to worsening diabetic retinopathy, likely due to rapid glucose reduction

Building new muscle mass in a caloric deficit is challenging for most people, and the primary goal should be muscle preservation rather than muscle gain

Metabolic Benefits: GLP-1 also helps your body manage blood sugar more effectively

Not all patients qualify

By offering one of the lowest entry points for GLP-1 treatment, Hers lowers a major barrier to care and gives people whove been priced out of brand-name meds a realistic way to get started

Missing a single dose is not significant